



CURING INFECTIONS.
 TREATING CHRONIC ILLNESS.
 IMPROVING QUALITY OF LIFE.
 CREATING TOMORROW'S ANTIBIOTICS.

www.cempra.com

Corporate fact sheet

Winter 2010

Corporate Overview

Founded in 2006, Cempra Pharmaceuticals develops differentiated antibacterials to address the increasing challenge of drug-resistant pathogens. Cempra's two clinical-stage candidates, CEM-101 and TAKSTA™ (CEM-102), address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and community. Cempra has leveraged its macrolide library of more than 500 compounds to identify CEM-101 as well as non-antibacterial candidates to treat chronic illnesses such as inflammatory diseases, endocrine diseases and gastric motility disorders.

Antibiotic Resistance and Opportunity

Antibiotic resistance has been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Adding to the threat is a decline in discovery and development of new and novel antibiotics that target resistant pathogens by the pharmaceutical industry. Antibiotic drug resistance has a significant impact on mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future. Cempra is focused on developing solutions to this problem and addressing the future needs of patients through development of two novel clinical-stage candidates: CEM-101 and TAKSTA™ (formerly CEM-102).

Management Team

Prabhavathi Fernandes, Ph.D., Founder, Pres. & CEO
 J. Gordon Still, M.D., Ph.D., Chief Medical Officer
 Drusilla Scott, Ph.D., R.A.C., Sen. VP of Regulatory Affairs
 Thorsten P. Degenhardt, Ph.D., VP of Drug Development
 Donald C. Olsen, EVP, Business Development
 David Pereira, Ph.D., Vice President of Chemistry

Board of Directors

Garheng Kong, M.D., Ph.D., M.B.A., Chairman
 Geeta Vemuri, Ph.D.
 Wistar Morris III, B.A., M.B.A.
 Dov A. Goldstein, M.D., M.B.A.
 John H. Johnson
 Michael L. Corrado, M.D., FIDSA
 Prabhavathi Fernandes, Ph.D., President and CEO

Scientific Advisory Board

Richard J. White, Ph.D., Chairman
 Christopher M. Cimarusti, Ph.D.
 J. Carl Craft, M.D.
 Sherwood L. Gorbach, M.D.
 David Krause, M.D.
 Ronald N. Jones, M.D.
 Ronald Nardi, Ph.D.
 André G. Pernet, Ph.D., M.B.A.
 Peter S. Ringrose, Ph.D.
 James V. Heck, Ph.D.
 Yoshi Ichikawa, Ph.D., Optimer Representative

Investors

Intersouth Partners
 Quaker BioVentures
 Wistar Morris III – Investment Banker
 Aisling Capital
 Teachers Private Capital
 Devon Park Bioventures

The Pipeline

Product	Indication	Preclinical	Phase I	Phase II	Phase III
CEM-101	Community Acquired Bacterial Pneumonia (CABP)				
	Oral Capsules	→			
	IV Formulation	→			
	Oral Suspension	→			
TAKSTA™ (CEM-102)	Acute Bacterial Skin Structure Infections (ABSSI)				
	Oral Tablets	→			
	Oral Suspension	→			

Corporate Headquarters:

Cempra Pharmaceuticals
 Building Four Quadrangle
 6340 Quadrangle Drive, Suite 100
 Chapel Hill, NC 27517
 (919) 467-1716

Media Inquiries:

Russo Partners, LLC
 Robert E. Flamm, Ph.D.
 (212) 845-4226
robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
 (212) 845-4251
tony.russo@russopartnersllc.com